Arrowhead Research Corp. (NASDAQ: ARWR) reported Q3 EPS of ($0.22), in-line with the analyst estimate of ($0.22).

ARC-520 Phase 2a Study Update

• Completed dosing of 1 mg/kg and 2 mg/kg dose cohorts
• Initial blinded data suggest that the magnitude of HBsAg knockdown is similar to non-human primate studies, including the chronically infected chimpanzee reported on previously
• Duration of knockdown appears to be substantially more sustained than in non-human primates, with patients in the 2 mg/kg group still demonstrating substantial knockdown after 8 weeks, which is the most recent time point available
• HBsAg levels appear to continue to decline in a number of patients at the 8 week time point in the 2 mg/kg group
• Based on initial review, dosing less frequent than once monthly will be explored in Phase 2b
• ARC-520 continues to be well tolerated, with no dropouts or serious adverse events reported
• The overall rate of AEs has been lower in the Phase 2a than in the Phase 1 normal volunteer study and safety labs continue to show no indication of end organ toxicity
• Enrolled and dosed additional subjects at 3 mg/kg in the still open normal volunteer study and the dose performed well, without detected differences from safety and tolerability results at the other doses. Overall AEs do not appear to be increasing in frequency or severity with dose
• Received IRB and DSMB approvals to proceed and began enrolling an additional dose cohort at 3 mg/kg in the Phase 2a patient study

For earnings history and earnings-related data on Arrowhead Research Corp. (ARWR) click here.